Tuesday, March 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Partnerships for Development of Therapeutics and Diagnostics for Biodefense

by Global Biodefense Staff
March 24, 2012

In response to threats presented by bioterrorism and emerging infectious diseases, the National Institute of Allergy and Infectious Disease (NIAID) Division of Microbiology and Infectious Diseases (DMID) has announced a research funding opportunity to facilitate development of countermeasures for certain pathogens and toxins.

NIAID invites research applications for projects focused on preclinical development of lead candidate therapeutics or medical diagnostics that address one or more NIAID Category A, B, or C priority pathogens to submit proposals under RFA-AI-12-017.

The focus of this effort is translation of basic research to product development, with an emphasis on development of countermeasures that are effective against multiple pathogens or toxins, development of technologies that can be widely applied to improve classes of products, and developing platforms that can reduce the time and cost of creating new products. This broad spectrum approach recognizes the expanding range of biological threats and the limited resources available to address each individual threat.

NIAID intends to commit $9.3 million in total costs in FY2013 to fund 10 to 15 applications in response to this announcement. Budgets for direct costs of up to $750,000 per year may be requested by each applicant. Additionally, applicants may request up to a total of $300,000 for major equipment in the first year of the award to ensure that research aims can be met and biohazards can be contained.

Organizations eligible for funding under this effort include academic, nonprofit, for profit and government entities. All applications must demonstrate substantive investment in the project by at least one industry participant.  Since academic organizations are often the source of new candidate products, collaborative partnerships between researchers from academic (or non-profit) and industrial disciplines are encouraged.

Full details are available under RFA-AI-12-017.  Letters of Intent are due by April 24, 2012.

Tags: BioterrorismRequest for Proposals

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC